Aktiesnakken — Maj 2010
-
ikke meget fetish over gen, men pinen er der

-
denne uges AU :For BioPorto havde vi på nuværende tidspunkt
forventet udmelding om licensaftaler med samarbejdspartnere
med henblik på salg af heterogene
NGAL test mod akut nyreskader. Positivt er det dog,
at selskabet holder fast i, at det er parat me -
Hvornår var det at man forventede godkendelse af algetas produkt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind